LabCorp (NYSE:LH) announces that it will adopt Thermo Fisher Scientific’s (NYSE:TMO) Ion Torrent Genexus Next-Generation Sequencing (NGS) Systems and Pan-Cancer Assay for use in research and development of companion diagnostics.
If cleared or approved for diagnostic use, the system may be available to smaller LabCorp laboratories, hospitals and other LH customers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.